Dr. Reddy’s Laboratories (NYSE:RDY – Get Rating) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Monday.

Several other research firms have also recently weighed in on RDY. Bank of America raised shares of Dr. Reddy’s Laboratories from a “neutral” rating to a “buy” rating in a research note on Friday, March 17th. JPMorgan Chase & Co. began coverage on Dr. Reddy’s Laboratories in a report on Monday, January 30th. They set an “underweight” rating for the company. Two analysts have rated the stock with a sell rating, two have assigned  a buy rating and one  has assigned  a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $67.00.

NYSE:RDY opened at $60.34 on Monday. Dr. Reddy’s Laboratories has a 1-year low of $49.59 and a 1-year high of $60.64. The company has a current ratio of 2.30, a quick ratio of 1.72 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $55.65 and a 200 day simple moving average of $54.37. The stock has a market capitalization of $10.05 billion, a PE ratio of 22.35, a P/E/G ratio of 0.48 and a beta of 0.49.

Dr. Reddy’s Laboratories (NYSE:RDY – Get Rating) last released its earnings results on Wednesday, January 25th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.31. Dr. Reddy’s Laboratories had a net margin of 15.15% and a return on equity of 20.63%. The business had revenue of $818.00 million during the quarter, compared to analysts’ expectations of $769.25 million.  On average, research analysts expect that  Dr. Reddy’s Laboratories will post 3.41 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the business. James Investment Research Inc. acquired a new stake in shares of  Dr. Reddy’s Laboratories during the fourth quarter worth $29,000.  Ronald Blue Trust Inc. lifted its holdings in shares of  Dr. Reddy’s Laboratories by 1,188.2% during the third quarter. Ronald Blue Trust Inc. now owns 979 shares of the company’s stock worth $54,000 after buying an additional 903 shares in the last quarter.  CWM LLC lifted its holdings in shares of  Dr. Reddy’s Laboratories by 24.0% during the fourth quarter. CWM LLC now owns 1,140 shares of the company’s stock worth $59,000 after buying an additional 221 shares in the last quarter.  Wipfli Financial Advisors LLC acquired a new stake in shares of  Dr. Reddy’s Laboratories during the third quarter worth $128,000.  Finally, Janiczek Wealth Management LLC lifted its holdings in shares of  Dr. Reddy’s Laboratories by 51.3% during the third quarter. Janiczek Wealth Management LLC now owns 2,596 shares of the company’s stock worth $136,000 after buying an additional 880 shares in the last quarter. Institutional investors and hedge funds own  9.81% of the company’s stock.

Dr. Reddy’s Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations.

Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.